2-(4-hydroxy-3-methoxy-phenyl)-propionic acid | 56355-43-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(4-hydroxy-3-methoxy-phenyl)-propionic acid
• 英文别名: 2-(4-hydroxy-3-methoxyphenyl)propanoic acid；methyl-4-hydroxy-3-methoxyphenylacetic acid；3-methoxy-4-hydroxyphenylpropionic acid；4-hydroxy-3-methoxyphenylpropanoic acid；4-hydroxy-3-methoxyphenylpropionic acid
• CAS: 56355-43-2
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: CJBZBOQPGGQIOM-UHFFFAOYSA-N

物化性质

• 沸点：
  355.0±32.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  壬胺 、 2-(4-hydroxy-3-methoxy-phenyl)-propionic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 2-(4-hydroxy-3-methoxyphenyl)-N-nonylpropanamide
  参考文献：
  名称：

  The SAR analysis of TRPV1 agonists with the α-methylated B-region

  摘要：

  A series of TRPV1 agonists with amide, reverse amide, and thiourea groups in the B-region and their corresponding alpha-methylated analogues were investigated. Whereas the alpha-methylation of the amide B-region enhanced the binding affinities and potencies as agonists, that of the reverse amide and thiourea led to a reduction in receptor affinity. The analysis indicated that proper hydrogen bonding as well as steric effects in the B-region are critical for receptor binding. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.059
• 作为产物：
  描述：

  高香草酸 在 palladium on activated charcoal 、 氢气 、 potassium carbonate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 16.5h， 生成 2-(4-hydroxy-3-methoxy-phenyl)-propionic acid
  参考文献：
  名称：

  The SAR analysis of TRPV1 agonists with the α-methylated B-region

  摘要：

  A series of TRPV1 agonists with amide, reverse amide, and thiourea groups in the B-region and their corresponding alpha-methylated analogues were investigated. Whereas the alpha-methylation of the amide B-region enhanced the binding affinities and potencies as agonists, that of the reverse amide and thiourea led to a reduction in receptor affinity. The analysis indicated that proper hydrogen bonding as well as steric effects in the B-region are critical for receptor binding. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.059

文献信息

• 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
  申请人：Seong Churlmin

  公开号：US20060084676A1

  公开（公告）日：2006-04-20

  The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

  本发明涉及作为5HT6受体拮抗剂的3-芳基-3-甲基喹啉-2,4-二酮化合物，其制备方法以及含有该化合物的用于治疗中枢神经系统疾病的药物组合物。根据本发明的3-芳基-3-甲基喹啉-2,4-二酮化合物可用于治疗与5HT6受体相关的疾病，因为其对5HT6受体具有优异的结合亲和力，并且对5HT6受体具有优异的选择性，而且相对于其他受体具有优异的选择性。
• COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR
  申请人：KYOTO UNIVERSITY

  公开号：US20160002600A1

  公开（公告）日：2016-01-07

  The present invention provides a composition for promoting cardiac differentiation of a pluripotent stem cell containing an EGFR inhibitor. The present invention also provides a kit for promoting cardiac differentiation containing an EGFR inhibitor and a method for inducing cardiac differentiation of a pluripotent stem cell comprising culturing the pluripotent stem cell in a medium containing an EGFR inhibitor.

  本发明提供了一种含有EGFR抑制剂的促进多能干细胞心脏分化的组合物。本发明还提供了一种含有EGFR抑制剂的促进心脏分化的试剂盒，以及一种诱导多能干细胞心脏分化的方法，包括在含有EGFR抑制剂的培养基中培养多能干细胞。
• 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP1650190A1

  公开（公告）日：2006-04-26

  The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones , or a pharmaceutically acceptable salt thereof acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

  本发明涉及3-芳基-3-甲基喹啉-2,4-二酮化合物或其药用可接受盐，作为5HT6受体拮抗剂，其制备方法以及含有该化合物的用于治疗中枢神经系统疾病的药物组合物。根据本发明的3-芳基-3-甲基喹啉-2,4-二酮化合物可用于治疗与5HT6受体相关的疾病，因为其对5HT6受体具有优异的结合亲和力，并且对于其他受体具有优异的选择性。
• Antioxidants
  申请人：Rudolph Thomas

  公开号：US20080152603A1

  公开（公告）日：2008-06-26

  The present invention relates to the use of compounds of the formula (I), with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

  本发明涉及使用式(I)中定义的基团化合物作为抗氧化剂，涉及对应的新型化合物和组合物，以及制备这些化合物和组合物的对应过程。
• Uv Protection
  申请人：Rudolph Thomas

  公开号：US20080171004A1

  公开（公告）日：2008-07-17

  The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

  本发明涉及使用那些本身在UV-A或UV-B区域不表现出显著UV吸收但在使用条件下具有反应性的化合物用于开发UV-A或UV-B保护，以及相应的新化合物和组合物，以及制备化合物和组合物的相应过程。